Abstract
Purpose. To perform an intra-arterial dose escalation studyof carboplatin based on hemispheric blood-flow estimation inpatients with recurrent malignant glioma. The primary purposewas to determine the maximally tolerated intra-arterial dose.Methods and patients. Methods included: 1) selective intra-arterialdelivery performed with modern microcatheters, 2) pulsatile infusion,and 3) dosage based on local cerebral blood-flowestimation (middle cerebral artery 60%, anterior cerebral artery20%, posterior cerebral artery 15%, and anterior choroidalartery 5% of the hemispheric blood-flow). The deliverieswere performed above the ophthalmic artery in theanterior circulation, or above the anterior inferior cerebellararteries in the posterior circulation. The doses wereescalated from 200 mg/hemisphere at 50 mg increments.Twenty-one patients were studied (14 with glioblastoma multiforme,five anaplastic astrocytoma, one aggressive low-grade glioma, onemetastasis). Patients had recurrent glioma limited to onehemisphere and Karnofsky score of 50 or greater.Concomitant therapies were allowed. Results. Carboplatin was escalatedto a dose of 1400 mg/hemisphere. One patienthad a permanent neuromotor decline. The predominant toxicitywas hematopoietic. The median time to tumor progressionwas 22 weeks, median survival 39 weeks, andthe response rate 70% (50% SD and 20%PR) of 19 patients. Conclusions. Hemispheric blood-flow estimationallowed us to escalate the dose of intra-arterialcarboplatin to twice what was previously considered safe.Responses compared favorably to previous studies. Further studiesare needed to determine if this method willprovide improved and durable responses.
Similar content being viewed by others
References
Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2597, 1993
. Ostrowski LE, von WM, Bigner SH, Rasheed A, Schold SJ, Brent TP, Mitra S, Bigner DD: Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines. Carcinogenesis 12: 1739–1744, 1991
Petersdorf SH, Livingston RB: High dose chemotherapy for the treatment of malignant brain tumors. J Neurooncol 20: 155–163, 1994
Fenstermacher J, Cowles A: Theoretic limitations of intracarotid infusions in brain tumor chemotherapy. Cancer Treatment Rep 61: 519–526, 1977
Stewart DJ, Benjamin RS, Zimmerman S: Clinical pharmacology of intra-arterial cis-diamminedichloroplatinum (II). Cancer Res 43: 917–920, 1983
Stewart DJ, Mikhael NZ, Nair RC, Kacew S, Montpetit V, Nanji A, Maroun JA, Howard K: Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol 11: 152–158, 1988
Shani J, Bertram J, Russel C, Dahalan R, Chen D, Parti R, Ahmadi J, Kempf R, Kawada T, Muggia F, Wolf W: Non-invasive monitoring of drug biodistribution and metabolism: Studies with intraarterial Pt-195m-cisplatin in humans. Cancer Res 49: 1877–1881, 1989
Nakagawa H, Fujita T, Izumimoto S, Miyawaki Y, Kubo S, Nakajima Y, Tsuruzono K, Kodama K, Higashiyama M, Doi O, et al.: Cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. II: Clinical effects. J Neurooncol 16: 69–76, 1993
Ginos JZ, Cooper AJ, Dhawan V, Lai JC, Strother SC, Alcock N, Rottenberg DA: [13N]Cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 28: 1844–1852, 1987
Stewart DJ: Pros and cons of intra-arterial chemotherapy. Oncology 3: 20–26, 1989
Shapiro WR, Green SB, Burger PC, Selker RG, vanGilder JC, Robertson JT, Mealey J, Ransohoff J, Mahaley MS: A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76: 772–781, 1992
Newton HB, Page MA, Junck L, Greenberg HS: Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurooncol 7: 39–45, 1989
Maiese K, Walker RW, Gargan R, Victor JD: Intra-arterial cisplatin–associated optic and otic toxicity. Arch Neurol 49: 83–86, 1992
Kupersmith M, Frohman L, Choi I, Foo S, Hiesenger E, Bereinstein A, Wise A, Carr R, Ransohoff J: Visual system toxicity following intra-arterial chemotherapy. Neurology 38: 284–289, 1988
Kupersmith MJ, Seiple WH, Holopigian K, Noble K, Hiesiger E, Warren F: Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Am J Ophthalmol 113: 435–438, 1992
Mahaley MJ, Hipp SW, Dropcho EJ, Bertsch L, Cush S, Tirey T, Gillespie GY: Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 70: 371–378, 1989
Dropcho EJ, Rosenfeld SS, Morawetz RB, Vitek J, Brothers M, Gorum T, Bell S, Gillespie GY, Glantz M, Mahaley MJ, et al.: Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. The CNS Cancer Consortium. J Clin Oncol 10: 452–458, 1992
Stewart DJ, Wallacer S, Feun L: A phase I study of intracarotid after infusion of cis-diamminedichloroplatinum (II) in patients with recurrent malignant intracerebral tumors. Cancer Res 42: 2059–2062, 1982
Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WK, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young SE, et al.: Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54: 794–799, 1984
Doz F, Berens ME, Dougherty DV, Rosenblum ML: Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J Neurooncol 11: 27–35, 1991
Yung WK, Mechtler L, Gleason MJ: Intravenous carboplatin for recurrent malignant glioma: A phase II study. J Clin Oncol 9: 860–864, 1991
Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE, Malec MK: A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 19: 69–74, 1994
Poisson M, Pereon Y, Chiras J, Delattre JY: Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol 10: 139–144, 1991
Follezou JY, Fauchon F, Chiras J: Intraarterial infusion of carboplatin in the treatment of malignant gliomas: A phase II study. Neoplasma 36: 349–352, 1989
Stewart DJ, Belanger JM, Grahovac Z, Curuvija S, Gionet LR, Aitken SE, Hugenholtz H, Benoit BG, DaSilva VF: Phase I study of intracarotid administration of carboplatin. Neurosurgery 30: 512–516; Discussion 516-517, 1992
Hyodo A, Yoshi Y, Tsurushima H, Matsumaru Y, Tsuboi K, Nose T: Superselective intra-arterial chemotherapy for treatment of malignant brain tumors. Comparative study with conventional IA chemotherapy. Neuroradiology 33 (Suppl): S192, 1991
Aoki S, Terada H, Kosuda S, Shitara N, Fujii H, Suzuki K, Kutsukake Y, Tanaka J, Sasaki Y, Okubo T, Shirouzu I, Machida T, Sasaki Y: Supraophthalmic chemotherapy with long tapered catheter: Distribution evaluated with intra-arterial and intravenous Tc-99m HMPAO. Radiology 188: 347–350, 1993
Bobo H, Kapp JP, Vance R: Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: Proposal of a new method of intra-arterial dosage calculation. J Neurooncol 13: 291–299, 1992
Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748–1756, 1989
Inamura T, Nomura T, Bartus RT, Black KL: Intracarotid infusion of RMP-7, a bradykinin analog: A method for selective drug delivery to brain tumors. J Neurosurg 81: 752–758, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cloughesy, T.F., Gobin, Y.P., Black, K.L. et al. Intra-arterial carboplatin chemotherapy for brain tumors: A dose escalation study based on cerebral blood flow. J Neurooncol 35, 121–132 (1997). https://doi.org/10.1023/A:1005856002264
Issue Date:
DOI: https://doi.org/10.1023/A:1005856002264